Glenn Heller
Overview
Explore the profile of Glenn Heller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
157
Citations
8611
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heller G, Devlin S
J R Stat Soc Ser C Appl Stat
. 2025 Jan;
74(1):83-99.
PMID: 39807176
Survival is poor for patients with metastatic cancer, and it is vital to examine new biomarkers that can improve patient prognostication and identify those who would benefit from more aggressive...
2.
Jensen J, Bobek O, Chan I, Miller B, Hillman D, Heller G, et al.
Clin Cancer Res
. 2024 Sep;
30(21):4910-4919.
PMID: 39287426
Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall...
3.
Choudhury N, Lai W, Makhnin A, Heller G, Eng J, Li B, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3697-3703.
PMID: 38940666
Purpose: Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted. Patients And Methods: This phase I/II trial...
4.
Zakrzewski J, Suh D, Markley J, Smith O, King C, Goldberg G, et al.
Nat Biotechnol
. 2024 Mar;
42(4):674.
PMID: 38531977
No abstract available.
5.
Stephan M, Ponomarev V, Brentjens R, Chang A, Dobrenkov K, Heller G, et al.
Nat Med
. 2024 Feb;
30(6):1788.
PMID: 38418853
No abstract available.
6.
Aggarwal R, Heller G, Hillman D, Xiao H, Picus J, Taplin M, et al.
J Clin Oncol
. 2024 Jan;
42(10):1114-1123.
PMID: 38261983
Purpose: Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone...
7.
Thummalapalli R, Choudhury N, Ehrich F, Beardslee T, Brazel D, Zhang S, et al.
JTO Clin Res Rep
. 2023 Aug;
4(8):100546.
PMID: 37644967
Introduction: Treatment with lorlatinib for patients with advanced - and -rearranged NSCLC (+ and + NSCLC) is associated with a unique set of adverse events (AEs) often requiring dose reduction....
8.
Heller G
J Stat Plan Inference
. 2023 Apr;
227:18-33.
PMID: 37035267
The continuous net reclassification improvement (NRI) statistic is a popular model change measure that was developed to assess the incremental value of new factors in a risk prediction model. Two...
9.
Morris M, Heller G, Hillman D, Bobek O, Ryan C, Antonarakis E, et al.
J Clin Oncol
. 2023 Mar;
41(18):3352-3362.
PMID: 36996380
Purpose: Enzalutamide and abiraterone both target androgen receptor signaling but via different mechanisms. The mechanism of action of one drug may counteract the resistance pathways of the other. We sought...
10.
Chow A, Uddin F, Liu M, Dobrin A, Nabet B, Mangarin L, et al.
Immunity
. 2022 Dec;
56(1):93-106.e6.
PMID: 36574773
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8 T cells. Here, we comprehensively profiled CD39 expression in...